Danaher to buy Masimo in $9.9 billion deal in diagnostics push

Danaher Corporation has announced its intention to acquire Masimo Corporation in a deal valued at $9.9 billion. This acquisition is part of Danaher’s strategy to enhance its capabilities in the diagnostics sector. The deal reflects Danaher’s ongoing commitment to expanding its portfolio in medical technology and diagnostics, which are critical areas for the company’s growth. Masimo is known for its innovative medical devices, particularly in non-invasive monitoring technologies. The acquisition will allow Danaher to integrate Masimo's advanced technologies into its existing product offerings, thereby strengthening its position in the healthcare market. The financial terms of the deal indicate a significant investment by Danaher, underscoring the importance of Masimo's products and technologies in the medical device landscape. Reports from both Reuters and the Financial Times confirm that the deal is nearing completion, with Danaher closing in on the acquisition. This move is seen as a strategic effort to bolster Danaher’s capabilities in diagnostics, which is a rapidly evolving field within the healthcare industry. The acquisition is expected to provide Danaher with enhanced resources and technologies that can improve patient outcomes and expand its market reach. Overall, the acquisition of Masimo by Danaher represents a significant development in the medical device sector, highlighting the ongoing consolidation and investment in healthcare technologies. The deal is anticipated to have implications for both companies and the broader market as they work to innovate and improve healthcare delivery.